PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Respiratory Syncytial Virus Vaccine, Adjuvanted, contains recombinant RSV glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This antigen is combined with GSK’s proprietary AS01E ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo ... shortly after the approval of GSK's recombinant RSVPreF3 ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV ... to invalidate three GSK patients covering its RSVPreF3 shot, according to a report on the Law360.com ...

Currently, there are no approved vaccines for RSV on the market, and Pfizer is in a close race with GSK to bring the first one to market. GSK’s rival jab now in the spotlight GSK’s RSVPreF3 ...

Getting the one-dose RSV vaccine is one of the easiest ways to do so. Over the last two years, Oklahoma City has seen an ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

He added: “As we head into the colder months, it’s so important that people who are at risk take advantage of the RSV vaccine ...

Credit: Getty Images Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD. While adults with IBD face a 2-fold increased risk for RSV ...